Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message| ()  

If you like to follow the buying trends of institutional investors and company insiders, pay attention to this list.

We ran a screen on stocks in the healthcare sector for those that have seen significant net institutional purchases over the current quarter and significant net insider purchases over the last six months.

Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the stocks mentioned below. Analyst ratings sourced from Zacks Investment Research.‬

We also created a price-weighted index of the stocks mentioned below, and monitored the performance of the list relative to the S&P 500 index over the last month. (To access a complete analysis of this list's recent performance, click here.)

Do you agree with insiders and institutions on these names? Use this list as a starting-off point for your own analysis.

List sorted by net institutional purchases as a percent of share float.

1. Sequenom Inc. (SQNM): Provides products, services, diagnostic testing, applications, and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural and livestock research. Market cap of $578.22M. Net institutional shares purchased over the current quarter at 11.4M, which is 12.72% of the company's 89.65M share float. Net insider shares purchased over the last six months at 32.85K, which is 0.04% of the company's 89.65M share float. The stock is a short0-squeeze candidate, with a short float at 19.41% (equivalent to 11.59 days of average volume). The stock has lost 6.27% over the last year.

2. Akorn, Inc. (AKRX): Engages in the manufacture and marketing of diagnostic and therapeutic pharmaceutical products, hospital drugs, and injectable pharmaceuticals in the United States and internationally. Market cap of $787.40M. Net institutional shares purchased over the current quarter at 7.8M, which is 11.55% of the company's 67.56M share float. Net insider shares purchased over the last six months at 33.50K, which is 0.05% of the company's 67.56M share float. The stock is a short-squeeze candidate, with a short float at 8.53% (equivalent to 6.01 days of average volume). The stock has gained 133.05% over the last year.

3. Genomic Health Inc. (GHDX): Focuses on the development and global commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Market cap of $652.32M. Net institutional shares purchased over the current quarter at 1.2M, which is 4.49% of the company's 26.75M share float. Net insider shares purchased over the last six months at 554.75K, which is 2.07% of the company's 26.75M share float. The stock is a short-squeeze candidate, with a short float at 9.45% (equivalent to 20.49 days of average volume). It's been a rough couple of days for the stock, losing 9.34% over the last week.

4. Theravance Inc. (THRX): Engages in the discovery, development, and commercialization of small-molecule medicines for various therapeutic areas, including respiratory disease, bacterial infections, and central nervous system pain. Market cap of $1.68B. Net institutional shares purchased over the current quarter at 1.9M, which is 4.37% of the company's 43.52M share float. Net insider shares purchased over the last six months at 5.19M, which is 11.92% of the company's 43.52M share float. The stock is a short-squeeze candidate, with a short float at 12.06% (equivalent to 18.36 days of average volume). The stock has gained 41.68% over the last year.

Insider data sourced from Yahoo Finance; institutional data sourced from Fidelity; all other data sourced from Finviz.

Source: 4 Healthcare Stocks With Smart Money And Insider Buying